Tay-Sachs Disease

Tay-Sachs disease is an inherited condition characterized by progressive destruction of nerve cells in the brain and spinal cord. This condition, caused by a defect in the HEXA gene, is passed from parent to child. Symptoms include blindness, dementia, and the inability to swallow. Tay-Sachs disease is rare among the general population, but occurs in approximately 1 in every 27 people of the Ashkenazi Jewish heritage.

What Is Tay-Sachs Disease?

Tay-Sachs disease is a rare, inherited disorder that causes progressive destruction of nerve cells located in the brain and spinal cord.
 

How Common Is It?

Tay-Sachs disease is rare in the general population. The genetic mutations that cause the disease are more common in people of Ashkenazi (eastern and central European) Jewish heritage than in those of other backgrounds. Approximately 1 in every 27 Jews in the United States is a carrier of gene.
 
The genetic mutations that cause Tay-Sachs disease are also more common in:
 
  • Certain French-Canadian communities of Quebec
  • Some Amish groups
  • The Cajun community of Louisiana.
     

Causes of Tay-Sachs Disease

Tay-Sachs disease is a condition that is passed from parent to child through a defect (mutation) of the HEXA gene located on chromosome number 15. The HEXA gene is responsible for making a vital enzyme called hexosaminidase-A (HEXA). Without HEXA, a fatty substance (lipid) called GM2 ganglioside accumulates abnormally in cells, especially in the nerve cells of the brain.
 
(Click Causes of Tay-Sachs to learn more.)
 

Is the Disease Inherited?

Tay-Sachs disease is an autosomal recessive condition, which means that both parents must have this defective gene in order for a child to inherit it.
 
When both parents are carriers (meaning that one HEXA gene is normal and one is defective but they have no symptoms), each child has a 25 percent chance of having the disease and a 50 percent chance of being a carrier.
 
(Click Inheriting Tay-Sachs for more information.)
 

Symptoms of Tay-Sachs Disease

Infants with Tay-Sachs disease appear to develop normally for the first few months of life. Then, as nerve cells become distended with fatty material, a relentless deterioration of mental and physical abilities occurs. The child becomes blind, deaf, and unable to swallow. Muscles begin to atrophy, and paralysis sets in.
 
Other symptoms of Tay-Sachs disease include:
 
A much rarer form of the disorder occurs in people in their 20s and early 30s, and is characterized by an unsteady gait and progressive neurological deterioration.
 
People with the disease also have "cherry-red" spots in their eyes.
 

Diagnosing Tay-Sachs Disease

When diagnosing Tay-Sachs disease, the healthcare provider will ask a number of questions about symptoms and family history, perform a physical exam, and recommend certain tests, including a blood test.
 
People with the disease, as well as carriers, can be identified by a simple blood test that measures HEXA activity. Prenatal diagnosis of Tay-Sachs disease is available, if desired.
 
(Click Tay-Sachs Testing for more information.)
 

Treatment for Tay-Sachs Disease

There is no cure for this condition or way of slowing down its progression. Therefore, treatment for Tay-Sachs disease focuses on controlling the symptoms. Some of these treatments may include:
 
  • Medications
  • Techniques to keep the airway open.
     
Treatment also focuses on lifestyle and care issues, including:
 
  • Feeding
  • Proper nutrition and hydration.
     

What Is the Prognosis?

Even with the best of care, children with Tay-Sachs disease usually die by age four from recurring infection. People with the adult-onset form of the disease can live full adult lives, although most become wheelchair-bound.
 

History of Tay-Sachs Disease

Tay-Sachs disease was named after two physicians. The first was the British physician, Warren Tay, who first described the red spot on the retina of the eye in 1881. The second was the American physician, Bernard Sachs, who described the changes that occur within cells and noted an increased prevalence in the eastern and central European Jewish (Ashkenazi) population.
 
Written by/reviewed by: Arthur Schoenstadt, MD
Last reviewed by: Arthur Schoenstadt, MD
Other Articles in This eMedTV Presentation